» Articles » PMID: 7051245

The Use of Trimethoprim-sulfamethoxazole in the Treatment of Chest Infections

Overview
Journal Rev Infect Dis
Date 1982 Mar 1
PMID 7051245
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The use of combinations of trimethoprim (TMP) and sulfamethoxazole (SMZ) for the treatment of chest infections is described. A number of studies have shown that TMP-SMZ is effective treatment for exacerbations of chronic bronchitis. The long-term use of TMP-SMZ as chemoprophylaxis of chronic bronchitis is also described. Conventional doses of TMP-SMZ (320 mg of TMP and 1600 mg of SMZ) have proved most effective in the prevention of chronic bronchitis; the drug combination is nontoxic and does not lead to the emergence of any resistant organisms. The use of TMP-SMZ for the treatment of pneumonia has been previously described. TMP-SMZ has also been found effective for long-term use in the treatment of cystic fibrosis.

Citing Articles

Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients.

Doud M, Light M, Gonzalez G, Narasimhan G, Mathee K Hum Genomics. 2010; 4(3):147-69.

PMID: 20368138 PMC: 3525977. DOI: 10.1186/1479-7364-4-3-147.


Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Stratton C Emerg Infect Dis. 2003; 9(1):10-6.

PMID: 12533275 PMC: 2873758. DOI: 10.3201/eid0901.020172.